You are here

Article Text

Article menu
Download PDFPDF
Brief communication
Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis
  1. Haruhiko Furusawa1,2,
  2. Anna L Peljto1,
  3. Avram D Walts1,
  4. Jonathan Cardwell1,
  5. Philip L Molyneaux3,
  6. Joyce S Lee1,
  7. Evans R Fernández Pérez4,
  8. Paul J Wolters5,
  9. Ivana V Yang1,
  10. David A Schwartz1
  1. 1 Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
  2. 2 Department of Respiratory Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Japan
  3. 3 Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK
  4. 4 Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado, USA
  5. 5 Pulmonary and Critical Care, University of California San Francisco, San Francisco, California, USA
  1. Correspondence to Dr David A Schwartz, Department of Medicine, University of Colorado, Denver, USA; david.schwartz{at}cuanschutz.edu

Abstract

A subset of patients with hypersensitivity pneumonitis (HP) develop lung fibrosis that is clinically similar to idiopathic pulmonary fibrosis (IPF). To address the aetiological determinants of fibrotic HP, we investigated whether the common IPF genetic risk variants were also relevant in study subjects with fibrotic HP. Our findings indicate that common genetic variants in TERC, DSP, MUC5B and IVD were significantly associated with fibrotic HP. These findings provide support for a shared etiology and pathogenesis between fibrotic HP and IPF.

  • hypersensitivity pneumonitis

https://doi.org/10.1136/thoraxjnl-2021-217693

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors IVY and DAS designed the study and provided quality control at each step of the project. HF, ADW, PLM, ERFP and PJW provided data and samples. HF performed the sample preparation. JSL, IVY and DAS supervised and coordinated the clinical and lab work assessment. HF, ALP and JC performed the data cleanings and analysis. HF and DAS wrote the original draft of the manuscript. All authors contributed to manuscript review, editing, and final approval for submission.

    • Funding This research was supported by grants from the NHLBI (R01-HL097163, R01-HL148437, P01- HL092870, UH3-HL123442 and UG3-HL151865) and DoD (W81XWH-17-1-0597).

    • Competing interests DAS reports grants from NIH-NHLBI, DOD, VAMC, and Eleven P15 during the conduct of the study; Travel support, patents, advisory board membership, ATS committee membership. Business collaboration with Eleven P15 and Vertex Pharmaceuticals. PJW reports grant from Boehringer Ingelheim during this study. ERFP reports grants from NIH-NHLBI, Colorado office of economic development and international trade research, Boehringer Ingelheim and Genentech during the study. Payment of honoraria for lectures from Boehringer Ingelheim speaker bureau. JSL reports a grant from NIH-NHLBI. ALP reports the consulting fee from ElevenP15. PLM is supported by an Action for Pulmonary Fibrosis Mike Bray fellowship and reports a grant from Boehringer Ingelheim, AstraZeneca and Roche. IVY, ADW, JC and HF declare no conflicts of interest associated with this manuscript.

    • Provenance and peer review Not commissioned; externally peer reviewed.